Besides, the ORR of PD-L1-positive patients were higher than the PD-L1 negative patients, which were 13.8% and 6.3%, respectively,4,87 suggesting that pembrolizumab treatment is effective for PD-L1-positive ESCC patients. Here, CD274 is linked to esophageal squamous cell carcinoma.